Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 1,043,600 | 1,049,300 | 1,117,500 | 1,773,600 | 1,555,400 |
| Cost of Goods | 681,300 | 705,400 | 693,100 | 748,100 | 524,000 |
| Gross Profit | 362,300 | 343,900 | 424,400 | 1,025,500 | 1,031,400 |
| Operating Expenses | 471,300 | 1,070,700 | 594,500 | 684,200 | 597,600 |
| Operating Income | -108,700 | -726,400 | -170,000 | 341,400 | 433,800 |
| Interest Expense | 71,000 | 87,900 | 37,300 | 34,500 | 31,300 |
| Other Income | 36,800 | 83,100 | -11,700 | -3,700 | 4,700 |
| Pre-tax Income | -142,900 | -731,200 | -219,000 | 303,200 | 407,200 |
| Income Tax | 47,700 | 29,300 | -7,400 | 83,700 | 102,100 |
| Net Income Continuous | -190,600 | -760,500 | -211,600 | 219,500 | 305,100 |
| Net Income | $-190,600 | $-760,500 | $-211,600 | $219,500 | $305,100 |
| EPS Basic Total Ops | -3.60 | -14.85 | -4.22 | 4.10 | 5.79 |
| EPS Basic Continuous Ops | -3.60 | -14.85 | -4.22 | 4.10 | 5.79 |
| EPS Diluted Total Ops | -3.60 | -14.85 | -4.22 | 4.06 | 5.67 |
| EPS Diluted Continuous Ops | -3.60 | -14.85 | -4.22 | 4.06 | 5.67 |
| EPS Diluted Before Non-Recurring Items | -0.23 | -6.23 | -2.23 | 6.02 | 7.88 |
| EBITDA(a) | $7,500 | $-361,800 | $-15,900 | $511,000 | $551,800 |